Sort:
Open Access Original Article Issue
Trends in incidence and mortality of acute kidney disease following coronary angiography in Chinese population: 2008–2017
Medicine Advances 2023, 1 (2): 123-132
Published: 20 June 2023
Downloads:19
Background

Acute kidney disease (AKD) has received increasing attention owing to its poor prognosis. However, few studies have investigated the trends in AKD incidence and prognosis among patients undergoing coronary angiography (CAG). Therefore, this study was designed to explore trends in the incidence and mortality of AKD following CAG in China.

Methods

We enrolled patients undergoing CAG using data of the Cardiorenal Improvement (CIN) cohort registry of Guangdong Provincial People's Hospital. Univariate and multivariate logistic regression analyses were applied to examine the incidence of AKD from 2008 to 2017. Mortality rates are presented as deaths per 1000 person‐years and were evaluated in univariate and multivariate Cox regression analyses.

Results

A total of 9665 patients (mean age: 61.6 ± 9.6 years, 40% women) were enrolled in the final analysis. From 2008 to 2017, the overall incidence and mortality of AKD were 19% and 323.0 per 1000 person‐years, respectively. The incidence of AKD decreased from 25% to 13% during 2008–2017 (adjusted odds ratio, 0.40; 95% confidence interval [CI], 0.31–0.51; p < 0.01; p for trend <0.01). However, the mortality of AKD increased significantly from 138.2 to 544.1 per 1000 person‐years (adjusted hazard ratio, 2.85; 95% CI, 1.20–6.73; p = 0.02, p for trend = 0.02). The above trends were observed consistently in patients stratified by sex and age.

Conclusions

Our findings suggest a significant decrease in incidence and an increase in mortality of AKD following CAG from 2008 to 2017 in China. We advocate for more proactive measures to prevent AKD and improve the prognosis of patients with AKD.

Open Access Case Report Issue
Should Paxlovid be prescribed for patients with severe COVID‐19 in the late course of infection? A case report
Medicine Advances 2023, 1 (1): 92-96
Published: 20 March 2023
Downloads:67

The infection of the coronavirus disease 2019 (COVID‐19) is often accompanied by pneumonia with both high incidence and mortality. Paxlovid is commonly prescribed in patients with mild and normal pneumonia within 5 days from the symptom onset. Herein, we report a practically effective use of Paxlovid compensatively in patients with COVID‐19 and severe pneumonia after 5 days of infection in a typical case in China. In this case, a 75‐year‐old man was diagnosed with severe COVID‐19 complicated with a pulmonary bacterial infection. After treatment with oxygen inhalation, Cefoperazone‐sulbactam and ambroxol, fever and upper respiratory symptoms were alleviated, except for the Oxygenation index (OI) remaining worse, Coronavirus was detected as positive, and levels of interleukin‐6 remained high. Paxlovid was prescribed for 5 days subsequently though it was 14 days since symptom onset. Thereafter, the nucleic acid of the patient turned negative in 7 days and the symptoms resolved. This case showed that Paxlovid can be considered in patients with COVID‐19 and severe pneumonia even in the later course of infection in clinical practice in China.

total 2